Actively Recruiting
Etoricoxib in Patients With Parkinsonian Disease
Led by Ihab Elsayed Hassan · Updated on 2026-04-08
60
Participants Needed
1
Research Sites
94 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Neuroinflammation is considered one of the most important factors contributing critically to pathophysiology of PD . Recently, high mobility group box-1 (HMGB1) protein has been encoded as a potential inflammatory biomarker in PD. HMGB1 mediates immune response mostly through endothelial cells and macrophage activation via targeting two vital cell receptors; Toll-like receptor 4 (TLR4) and advanced glycation end products (RAGE).
CONDITIONS
Official Title
Etoricoxib in Patients With Parkinsonian Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 63 18 years
- Both male and female will be included
- Patients diagnosed with PD according to Unified Parkinson's Disease Rating Scale
You will not qualify if you...
- Breast feeding
- Patients with significant liver and kidney function abnormalities
- Alcohol and / or drug abusers
- Patients with known allergy to the study medications
- Pregnant women and women with planned pregnancy
- Patients who are currently using other anti-inflammatory drugs
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Mansoura University
Al Mansurah, Egypt, 26548
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here